Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient

Katsuyasu Saigo Blood Transfusion Division, Kobe University Hospital, Kobe, JapanCorrespondence[email protected]

Yasuyo Okumachi Department of Medicine, Kakogawa Municipal Hospital, Kakogawa, Hyogo, Japan

Shin-Ichi Kondo Department of Medicine, Kakogawa Municipal Hospital, Kakogawa, Hyogo, Japan

Tadanobu Chinzei Department of Medicine, Kakogawa Municipal Hospital, Kakogawa, Hyogo, Japan

Akiharu Okamura Department of Pathology, Kakogawa Municipal Hospital, Kakogawa, Hyogo, Japan

Mariko Takenokuchi Clinical Laboratory, Kobe University Hospital, Kobe, Japan

Seiji Kawano Clinical Laboratory, Kobe University Hospital, Kobe, Japan

Shunichi Kumagai Blood Transfusion Division, Kobe University Hospital, Kobe, Japan; Clinical Laboratory, Kobe University Hospital, Kobe, Japan

show all

Abstract

A 48-year-old male patient with follicular lymphoma, grade II, stage IV, was treated with CHOP, ESHAP and MACOP-B, resulting in partial remission. After 9 months, the disease progressed and several chemotherapy agents, including three courses of rituximab combined with etoposide, sobuzoxane or methotrexate, only resulted in a stable disease response. However, the fourth course of rituximab combined with a small dose of melphalan produced excellent results and the complete response continued for more than 15 months. It is possible that these two drugs may act synergistically.

Keywords:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient

Information for

Open access

Opportunities

Help and information

Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature